Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$1.86 -1.9%	$1.98	$1.64 ▼ $7.67	$22.82M	0.81	80,490 shs	9,848 shs
CRBP Corbus Pharmaceuticals	$7.23 -1.8%	$6.53	$4.64 ▼ $61.90	$88.47M	3.19	354,871 shs	92,611 shs
CRDL Cardiol Therapeutics	$1.28 +10.3%	$1.04	$0.77 ▼ $3.12	$105.74M	0.98	361,690 shs	446,190 shs
TVRD Cara Therapeutics	$30.86 -7.6%	$0.00	$8.13 ▼ $34.31	$96.13M	0.21	20,607 shs	68,778 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	-1.85%	-3.39%	-8.62%	-21.40%	-49.73%
CRBP Corbus Pharmaceuticals	-1.77%	-2.43%	-3.60%	-1.36%	-83.06%
CRDL Cardiol Therapeutics	+10.34%	+20.75%	+18.52%	+8.47%	-45.42%
TVRD Cara Therapeutics	-7.58%	+3,085,999,900.00%	+3,085,999,900.00%	+3,085,999,900.00%	+3,085,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	3.9113 of 5 stars	3.5	3.0	0.0	4.3	2.6	1.7	0.0
CRBP Corbus Pharmaceuticals	4.1071 of 5 stars	4.6	0.0	0.0	4.7	3.2	1.7	0.0
CRDL Cardiol Therapeutics	2.4123 of 5 stars	3.7	4.0	0.0	0.0	2.2	0.0	0.6
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	115.63% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$50.88	603.67% Upside
CRDL Cardiol Therapeutics	3.40	Buy	$8.67	577.08% Upside
TVRD Cara Therapeutics	3.00	Buy	$65.00	110.63% Upside

Current Analyst Ratings Breakdown

Latest CASI, CRDL, TVRD, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	TVRD Cara Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/7/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	CRBP Corbus Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$65.00 ➝ $58.00
5/7/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $56.00
5/7/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/12/2025	CRBP Corbus Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$51.00
3/12/2025	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $50.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$31.37M	0.73	N/A	N/A	$1.81 per share	1.02
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	($1.56) per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.32 per share	N/A
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$26.94M	-$2.55	N/A	∞	N/A	-143.18%	-181.52%	-45.72%	8/15/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$44.60M	-$4.22	N/A	N/A	N/A	N/A	-42.28%	-32.92%	8/5/2025 (Estimated)
CRDL Cardiol Therapeutics	-$20.84M	-$0.34	N/A	N/A	N/A	N/A	-194.40%	-129.07%	7/14/2025 (Estimated)
TVRD Cara Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CASI, CRDL, TVRD, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/6/2025	Q1 2025	CRBP Corbus Pharmaceuticals	-$1.26	-$1.39	-$0.13	-$1.39	N/A	N/A
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
3/11/2025	Q4 2024	CRBP Corbus Pharmaceuticals	-$1.02	-$0.78	+$0.24	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	1.38	3.20	2.32
CRBP Corbus Pharmaceuticals	N/A	13.84	13.84
CRDL Cardiol Therapeutics	0.01	2.49	2.49
TVRD Cara Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
CRBP Corbus Pharmaceuticals	64.64%
CRDL Cardiol Therapeutics	12.49%
TVRD Cara Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
CRBP Corbus Pharmaceuticals	4.00%
CRDL Cardiol Therapeutics	5.25%
TVRD Cara Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	12.20 million	Optionable
CRBP Corbus Pharmaceuticals	40	12.24 million	11.69 million	Optionable
CRDL Cardiol Therapeutics	20	82.61 million	78.27 million	Not Optionable
TVRD Cara Therapeutics	80	3.12 million	N/A	N/A

CASI, CRDL, TVRD, and CRBP Headlines

Recent News About These Companies

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27 at 8:00 AM | businesswire.com

Cara Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

May 27 at 1:15 AM | americanbankingnews.com

Cara Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Oppenheimer

May 26 at 6:10 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
By Jeffrey Neal Johnson | May 14, 2025
View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
By Jeffrey Neal Johnson | May 14, 2025
View Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

CASI, CRDL, TVRD, and CRBP Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$1.86 -0.04 (-1.85%)

Closing price 05/28/2025 03:50 PM Eastern

Extended Trading

$1.88 +0.02 (+1.35%)

As of 05/28/2025 06:59 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Corbus Pharmaceuticals NASDAQ:CRBP

$7.23 -0.13 (-1.77%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$7.39 +0.16 (+2.20%)

As of 04:05 AM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$1.28 +0.12 (+10.34%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.02 (+1.56%)

As of 04:00 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cara Therapeutics NASDAQ:TVRD

$30.86 -2.53 (-7.58%)

As of 05/28/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time